Search
Results: 7
Abnormal dopaminergic modulation of striato-cortical networks underlies levodopa-induced dyskinesias in humans.
Damian M Herz, Brian N Haagensen, Mark S Christensen, Kristoffer H Madsen, James B Rowe, Annemette Løkkegaard, Hartwig R Siebner
Feb 02, 2016
Parkinson's Disease Connectivity Dynamic causal modelling Functional MRI levodopa-induced dyskinesia Aged Aged 80 and over Antiparkinson Agents Dopaminergic Neurons Dyskinesia Drug-Induced Female Functional Neuroimaging Humans Levodopa Magnetic Resonance Imaging Male Middle Aged Motor Cortex Neural Pathways Psychomotor Performance Putamen
A Disease Progression Model to Quantify the Nonmotor Symptoms of Parkinson's Disease in Participants With Leucine-Rich Repeat Kinase 2 Mutation.
Malidi Ahamadi, Nitin Mehrotra, Nathan Hanan, Ka Lai Yee, Ferdous Gheyas, Judith Anton, Massimo Bani, Babak Boroojerdi, Hans Smit, Jonas Weidemann, Sreeraj Macha, Vincent Thuillier, Chao Chen, Minhua Yang, Caroline H Williams-Gray, Glenn T Stebbins, Gennaro Pagano, Yaming Hang, Kenneth Marek, Charles S Venuto, Monica Javidnia, David Dexter, Anne Pedata, Bob Stafford, Mussie Akalu, Diane Stephenson, Klaus Romero, Vikram Sinha, Critical Path for Parkinson’s Consortium
Mar 19, 2021
Leucine-rich repeat kinase 2 (LRRK2) inhibitors are currently in clinical development as interventions to slow progression of Parkinson's disease (PD). Understanding the rate of progression in PD as measured by both motor and...
Adult Age Factors Aged Aged 80 and over Antiparkinson Agents Databases Factual Disease Progression Female Glucosylceramidase Heterozygote Humans Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 Longitudinal Studies Male Middle Aged Models Theoretical Mutation Parkinson Disease Predictive Value of Tests Severity of Illness Index ALPHA-SYNUCLEIN
Cholinergic and perfusion brain networks in Parkinson disease dementia.
Sean J Colloby, Ian G McKeith, David J Burn, David J Wyper, John T O'Brien, John-Paul Taylor
Apr 21, 2016
Aged Antiparkinson Agents Brain Brain Mapping Cerebrovascular Circulation Donepezil Female Humans Indans Linear Models Male Mental Status Schedule Multivariate Analysis Neural Pathways Nootropic Agents Parkinson Disease Piperidines Radiopharmaceuticals Receptor Muscarinic M1 Receptor Muscarinic M4 Receptors Muscarinic Tomography Emission-Computed Single-Photon
L-dopa responsiveness in early Parkinson's disease is associated with the rate of motor progression.
Naveed Malek, Sofia Kanavou, Michael A Lawton, Vanessa Pitz, Katherine A Grosset, Nin Bajaj, Roger A Barker, Yoav Ben-Shlomo, David J Burn, Tom Foltynie, John Hardy, Nigel M Williams, Nicholas Wood, Huw R Morris, Donald G Grosset, PRoBaND clinical consortium
Jul 25, 2019
BACKGROUND: L-dopa responsiveness in Parkinson's disease (PD) varies, but the clinical correlates and significance of this are ill-defined. METHODS: Patients were assessed before and after their usual morning L-dopa dose, using...
Exploring the multifactorial aspects of Gut Microbiome in Parkinson's Disease.
Sujith Pavan, Arvind N Prabhu, Sankar Prasad Gorthi, Bhabatosh Das, Ankur Mutreja, Vignesh Shetty, Thandavarayan Ramamurthy, Mamatha Ballal
Oct 01, 2022
Motor complications in Parkinson's disease
Han-Joon Kim, Sarah Mason, Thomas Foltynie, Sophie Winder-Rhodes, Roger A Barker, Caroline H Williams-Gray
Sep 11, 2019
Impulse control disorders and levodopa-induced dyskinesias in Parkinson's disease
V Voon, TC Napier, MJ Frank, V Sgambato-Faure, AA Grace, M Rodriguez-Oroz, J Obeso, E Bezard, P-O Fernagut
Mar 17, 2017
Dopaminergic medications used in the treatment of patients with Parkinson's disease are associated with motor and non-motor behavioural side-effects, such as dyskinesias and impulse control disorders also known as behavioural...